Biogen Idec snags blockbuster approval for oral MS drug

Biogen Idec ($BIIB) picked up U.S. approval for its oral multiple sclerosis drug, Tecfidera, or BG-12, already touted as a sure blockbuster. At least two other oral MS drugs--Sanofi's ($SNY) Aubagio and Novartis' ($NVS) Gilenya--have reached the market, but they don't come with the credentials or safety rating Tecfidera brings to the table. Late-stage clinical trials showed the drug could cut MS relapse rate by about half, and the FDA said in a release that, because there is no cure for MS, it is important to have a variety of treatment options. Multiple sclerosis is one of the most common causes of neurological disabilities in young adults, and analysts think Tecfidira could earn more than $3 billion a year for Biogen Idec out of a $12 billion market. FierceBiotech's story | More

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…